Stocks making the biggest moves premarket: Snowflake, Moderna, Broadcom & more
Snowflake shares surged 24% after Q2 results beat estimates, with revenue of $1.55B and EPS of $0.62. Broadcom fell 2.5% on lower Q4 revenue forecasts. Campbell's dropped 7% on weak fiscal 2027 guidance. Ultragenyx plunged 46% after a failed drug trial. Petco rose 9% on strong Q2 margins. Moderna declined 2% after a downgrade. Argan gained 7.5% on better-than-expected earnings. Five Below rose 4.5% on strong Q2 results. Victoria's Secret fell 18% on missed revenue estimates. Netskope rose 12% on
How this was made
The 30-second read
Why it matters
Multiple primary disclosures drive divergent price moves; traders must assess each ticker individually.
Market read
High relevance for short‑term traders targeting earnings-driven volatility.
What to watch
Supply‑chain constraints and macro backdrop could temper upside despite earnings beats.
Background
Premarket roundup of U.S. stocks reporting earnings, guidance, and trial outcomes.
Ticker impact
Snowflake shares surged 24% after Q2 results beat expectations and raised full-year product revenue guidance.
Continued pre‑market rally into open, potential further gains if guidance holds.
Earnings beat and guidance raise are fresh primary disclosures driving a large price move.
HPE slipped 3% while forecasting FY earnings growth of 16‑20% versus consensus 18.7% and cash flow at least $5 bn.
Potential downside pressure in early trade.
Guidance miss is a primary disclosure affecting valuation.
Broadcom fell 2.5% after Q4 revenue forecast of $34.8 bn missed $35.03 bn estimate and margin guidance fell short.
Likely further decline in pre‑market trading.
Fresh forecast miss is a primary catalyst.
Campbell's dropped ~7% after FY2027 earnings guidance of $1.65‑$1.80 missed $1.83 consensus.
Continued downside risk in early session.
Guidance miss is a new data point.
Ultragenyx plunged >46% after Phase 3 trial for Angelman syndrome failed to meet primary endpoint.
Further decline expected as investors reassess pipeline.
Clinical trial failure is a material, primary disclosure.
Moderna fell >2% after being downgraded to sell by Rothschild & Co Redburn.
Likely modest further decline.
Analyst downgrade is a new catalyst but modest impact.
Five Below rose 4.5% after Q2 earnings of $1.68 per share and revenue of $1.26 bn beat expectations.
Potential further gains in early trade.
Earnings beat is a primary disclosure.
NetApp dropped 8% after Q1 deferred revenue of $4.85 bn missed $4.86 bn estimate and margin beat.
Likely further downside in pre‑market.
Fresh revenue guidance is primary news.
Market effects
Software and biotech sectors see mixed reactions; earnings beats lift peers while misses drag them.
U.S. pre‑market activity influenced by multiple earnings releases across technology and consumer staples.
Limited to U.S. listed companies; no broader macro impact.
Counterpoint
Some stocks (e.g., Moderna) may rebound if downgrade sentiment fades; others (e.g., Ultragenyx) could be oversold after trial failure.
Key entities
- companySnowflake
Cloud data‑warehousing firm
- companyBroadcom
Semiconductor and infrastructure software
- companyUltragenyx
Biotech focused on rare diseases
